Morgan Stanley’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-155,390
| Closed | -$233K | – | 7779 |
|
|
2023
Q1 | $233K | Buy |
155,390
+108,995
| +235% | +$147K | ﹤0.01% | 5641 |
|
|
2022
Q4 | $46.3K | Sell |
46,395
-26,853
| -37% | -$36.2K | ﹤0.01% | 6326 |
|
|
2022
Q3 | $131K | Sell |
73,248
-76,335
| -51% | -$221K | ﹤0.01% | 5942 |
|
|
2022
Q2 | $434K | Sell |
149,583
-137,819
| -48% | -$340K | ﹤0.01% | 5489 |
|
|
2022
Q1 | $794K | Sell |
287,402
-160,928
| -36% | -$506K | ﹤0.01% | 5132 |
|
|
2021
Q4 | $2.09M | Buy |
448,330
+318,953
| +247% | +$1.99M | ﹤0.01% | 4552 |
|
|
2021
Q3 | $1.1M | Sell |
129,377
-27,203
| -17% | -$384K | ﹤0.01% | 4990 |
|
|
2021
Q2 | $2.57M | Buy |
156,580
+155,079
| +10,332% | +$3.13M | ﹤0.01% | 4445 |
|
|
2021
Q1 | $33K | Sell |
1,501
-19,821
| -93% | -$540K | ﹤0.01% | 6552 |
|
|
2020
Q4 | $659K | Buy |
21,322
+17,477
| +455% | +$442K | ﹤0.01% | 4908 |
|
|
2020
Q3 | $78K | Sell |
3,845
-136,269
| -97% | -$2.39M | ﹤0.01% | 5540 |
|
|
2020
Q2 | $2.15M | Buy |
140,114
+133,630
| +2,061% | +$1.54M | ﹤0.01% | 3521 |
|
|
2020
Q1 | $50K | Sell |
6,484
-15,734
| -71% | -$193K | ﹤0.01% | 5467 |
|
|
2019
Q4 | $317K | Buy |
22,218
+18,342
| +473% | +$284K | ﹤0.01% | 5177 |
|
|
2019
Q3 | $59K | Buy |
3,876
+3,823
| +7,213% | +$59.6K | ﹤0.01% | 5652 |
|
|
2019
Q2 | $1K | Sell |
53
-819
| -94% | -$13.1K | ﹤0.01% | 6589 |
|
|
2019
Q1 | $15K | Buy |
+872
| New | +$15.5K | ﹤0.01% | 6097 |
|
Morgan Stanley's TCRR Position: Q2 2023 in Review
Morgan Stanley sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 155,390 shares — an estimated $233K sold.
Morgan Stanley first reported a position in TCRR in Q1 2019 and held it in 17 quarters. The position peaked at $2.57M in Q2 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.
- Morgan Stanley reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Morgan Stanley sold 155,390 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $233K.
- Morgan Stanley first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2019 and held it in 17 quarters.
- Morgan Stanley's TCR2 Therapeutics Inc. Common Stock position peaked at $2.57M in Q2 2021.
- 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.
Based on Morgan Stanley's 13F filing for Q2 2023, filed 14 Aug 2023.